These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21612933)

  • 41. Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity.
    Cheng KF; Al-Abed Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3376-9. PubMed ID: 16682188
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluation of isoxazole, oxazole, and oxadiazole containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
    Jadhav RD; Kadam KS; Kandre S; Guha T; Reddy MM; Brahma MK; Deshmukh NJ; Dixit A; Doshi L; Potdar N; Enose AA; Vishwakarma RA; Sivaramakrishnan H; Srinivasan S; Nemmani KV; Gupte A; Gangopadhyay AK; Sharma R
    Eur J Med Chem; 2012 Aug; 54():324-42. PubMed ID: 22683241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice.
    Peng XD; Wu XH; Chen LJ; Wang ZL; Hu XH; Song LF; He CM; Luo YF; Chen ZZ; Jin K; Lin HG; Li XL; Wang YS; Wei YQ
    J Pharmacol Exp Ther; 2010 Jan; 332(1):46-56. PubMed ID: 19828878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1,2,5-Oxadiazole analogues of leflunomide and related compounds.
    Giorgis M; Lolli ML; Rolando B; Rao A; Tosco P; Chaurasia S; Marabello D; Fruttero R; Gasco A
    Eur J Med Chem; 2011 Jan; 46(1):383-92. PubMed ID: 21109332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and evaluation of novel 2,3,5-triaryl-4H,2,3,3a,5,6,6a-hexahydropyrrolo[3,4-d]isoxazole-4,6-diones for advanced glycation end product formation inhibitory activity.
    Kaur A; Singh B; Jaggi AS
    Bioorg Med Chem Lett; 2013 Feb; 23(3):797-801. PubMed ID: 23290454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors.
    Yun W; Ahmad M; Chen Y; Gillespie P; Conde-Knape K; Kazmer S; Li S; Qian Y; Taub R; Wertheimer SJ; Whittard T; Bolin D
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7205-9. PubMed ID: 22001092
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and biological evaluation of a new series of phenothiazine-containing protein farnesyltransferase inhibitors.
    Abuhaie CM; Ghinet A; Farce A; Dubois J; Gautret P; Rigo B; Belei D; Bîcu E
    Eur J Med Chem; 2013 Jan; 59():101-10. PubMed ID: 23207411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation.
    Graham TH; Liu W; Verras A; Sebhat IK; Xiong Y; Bleasby K; Bhatt UR; Chen Q; Garcia-Calvo M; Geissler WM; Gorski JN; He H; Lassman ME; Lisnock J; Li X; Shen Z; Tong X; Tung EC; Wiltsie J; Xiao J; Xie D; Xu S; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2811-7. PubMed ID: 22444683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes.
    Graham TH; Liu W; Verras A; Reibarkh M; Bleasby K; Bhatt UR; Chen Q; Garcia-Calvo M; Geissler WM; Gorski JN; He H; Lassman ME; Lisnock J; Li X; Shen Z; Tong X; Tung EC; Wiltsie J; Xie D; Xu S; Xiao J; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2818-22. PubMed ID: 22444685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring isoxazoles and pyrrolidinones decorated with the 4,6-dimethoxy-1,3,5-triazine unit as human farnesyltransferase inhibitors.
    Lucescu L; Ghinet A; Shova S; Magnez R; Thuru X; Farce A; Rigo B; Belei D; Dubois J; Bîcu E
    Arch Pharm (Weinheim); 2019 May; 352(5):e1800227. PubMed ID: 30947375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lead optimization of isocytosine-derived xanthine oxidase inhibitors.
    Bajaj K; Burudkar S; Shah P; Keche A; Ghosh U; Tannu P; Khanna S; Srivastava A; Deshmukh NJ; Dixit A; Ahire Y; Damre A; Nemmani KV; Kulkarni-Almeida A; B-Rao C; Sharma R; Sivaramakrishnan H
    Bioorg Med Chem Lett; 2013 Feb; 23(3):834-8. PubMed ID: 23265878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insight into the medicinal chemistry of the endocannabinoid hydrolase inhibitors.
    Kapanda CN; Poupaert JH; Lambert DM
    Curr Med Chem; 2013; 20(14):1824-46. PubMed ID: 23410152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New lead structures in the isoxazole system: relationship between quantum chemical parameters and immunological activity.
    Maczyński M; Ryng S; Artym J; Kocieba M; Zimecki M; Brudnik K; Jodkowski JT
    Acta Pol Pharm; 2014; 71(1):71-83. PubMed ID: 24779196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary on BIA 10-2474.
    Hayes AW
    Regul Toxicol Pharmacol; 2020 Mar; 111():104541. PubMed ID: 31759139
    [No Abstract]   [Full Text] [Related]  

  • 55. Bile salt hydrolases: Structure and function, substrate preference, and inhibitor development.
    Dong Z; Lee BH
    Protein Sci; 2018 Oct; 27(10):1742-1754. PubMed ID: 30098054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isoxazole Derivatives as Regulators of Immune Functions.
    Zimecki M; Bąchor U; Mączyński M
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30360408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inspired by Nature: The 3-Halo-4,5-dihydroisoxazole Moiety as a Novel Molecular Warhead for the Design of Covalent Inhibitors.
    Pinto A; Tamborini L; Cullia G; Conti P; De Micheli C
    ChemMedChem; 2016 Jan; 11(1):10-4. PubMed ID: 26607551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies.
    Lima PA; Berg BB; Castor MGME
    Intest Res; 2022 Oct; 20(4):392-417. PubMed ID: 35645322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33).
    Mączyński M; Regiec A; Sochacka-Ćwikła A; Kochanowska I; Kocięba M; Zaczyńska E; Artym J; Kałas W; Zimecki M
    Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34063515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019.
    Nagarkatti P; Miranda K; Nagarkatti M
    Front Pharmacol; 2020; 11():589438. PubMed ID: 33240092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.